Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.035,69
-1,57%
NASDAQ Composite
15.657,82
-2,04%
Bitcoin
60.448,70
-5,31%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ SAB Biotherapeutics Inc (SABSW) SAB Biotherapeutics Inc (SABSW) Notizie

SAB Biotherapeutics Inc

SABSW
0,035
0,0046 (15,13%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 22:02:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Warrant Azionario
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
16/4/202413:15GLOBESAB Biotherapeutics Provides SAB-142 Trial Update
08/4/202413:15GLOBESAB Biotherapeutics to Present at INNODIA Annual Meeting
04/4/202413:15GLOBESAB Biotherapeutics to Present at the Needham Virtual..
29/3/202412:15GLOBESAB Biotherapeutics Reports Full Year 2023 Operating and..
25/3/202415:15GLOBESAB Biotherapeutics Announces Clinical Partnership with..
23/2/202414:00GLOBESAB Biotherapeutics to Present at the BIO CEO & Investor..
08/2/202414:00GLOBESAB Biotherapeutics to Present at the Oppenheimer..
02/2/202413:30GLOBESAB Biotherapeutics Announces Executive Leadership Change
23/1/202423:58GLOBESAB Biotherapeutics Regains Compliance with Nasdaq Minimum..
02/1/202422:30GLOBESAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
29/11/202313:30GLOBESAB Biotherapeutics Announces Commencement of the HUMAN..
20/11/202313:30GLOBESAB Biotherapeutics Appoints Katie Ellias to the Board of..
14/11/202313:30GLOBESAB Biotherapeutics Announces Completion of $67.1 Million..
14/11/202313:15GLOBESAB Biotherapeutics Announces Q3 2023 Financial Results and..
09/11/202313:30GLOBESAB Biotherapeutics to Present at Piper Sandler Healthcare..
24/10/202313:30GLOBESAB Biotherapeutics Appoints Michael G. King Jr. as Chief..
19/10/202313:30GLOBESAB Biotherapeutics Receives Australian Approval to Commence..
05/10/202313:30GLOBESAB Biotherapeutics Approves Appointment of Andrew Moin to..
02/10/202313:30GLOBESAB Biotherapeutics Announces Private Placement of up to..
21/8/202314:30GLOBESAB Biotherapeutics Provides Company Update for Q2..
21/6/202314:30GLOBESAB Biotherapeutics Presents Positive IND-Enabling GLP..
30/5/202314:30GLOBESAB Biotherapeutics to Present Novel Human IgG Platform with..
19/5/202314:30GLOBESAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio..
16/5/202314:30GLOBESAB Biotherapeutics Provides Company Update for Q1 2023..
12/5/202314:30GLOBESAB Biotherapeutics Announces First Publication of Promising..
09/5/202314:30GLOBESAB Biotherapeutics Announces Progress on U.S. FDA’s Phased..
04/5/202314:30GLOBESAB Biotherapeutics Presents Positive Phase 1 and 2a Data..
03/5/202323:00GLOBESAB Biotherapeutics to Present at Sidoti Virtual Investor..
Apertura: 0,035 Min: 0,035 Max: 0,035
Chiusura: 0,0304

La tua Cronologia

NASDAQ
SABSW
SAB Biotherapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network